Protagonist Therapeutics, which is developing peptide-based oral drugs for gastrointestinal diseases, announced terms for its IPO on Monday.
The Milpitas, CA-based company plans to raise $70 million by offering 5.8 million shares at a price range of $11 to $13. Insiders intend to purchase $40 million worth of shares in the offering. At the midpoint of the proposed range, Protagonist Therapeutics would command a fully diluted market value of $189 million.
The Milpitas, CA-based company plans to raise $70 million by offering 5.8 million shares at a price range of $11 to $13. Insiders intend to purchase $40 million worth of shares in the offering. At the midpoint of the proposed range, Protagonist Therapeutics would command a fully diluted market value of $189 million.
